SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma - Quaterly Results

29 Oct 2021 Evaluate
The September 2021 quarter revenue stood at Rs. 8237.10 millions, up 21.76% as compared to Rs. 6765.10 millions during the corresponding quarter last year.The Net Profit of the company registered a slight decline of -12.60% to Rs. 1968.50  millions from Rs. 2252.20 millions.A decline of 2852.60 millions was observed in the OP in the quarter ended September 2021 from 3370.80 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 8237.10 6765.10 21.76 15664.30 12373.60 26.59 27185.90 21964.20 23.77
Other Income 524.10 862.40 -39.23 834.10 993.40 -16.04 1035.70 1842.00 -43.77
PBIDT 2852.60 3370.80 -15.37 5492.80 5236.10 4.90 10204.80 7169.80 42.33
Interest 0.70 13.50 -94.81 12.40 25.50 -51.37 69.00 91.00 -24.18
PBDT 2851.90 3357.30 -15.05 5480.40 5210.60 5.18 10135.80 7039.60 43.98
Depreciation 304.00 272.00 11.76 601.60 540.60 11.28 1114.90 912.90 22.13
PBT 2547.90 3085.30 -17.42 4878.80 4670.00 4.47 9020.90 6126.70 47.24
TAX 579.40 833.10 -30.45 975.70 1260.90 -22.62 2264.50 1715.40 32.01
Deferred Tax 30.80 91.60 -66.38 63.40 138.70 -54.29 97.70 34.50 183.19
PAT 1968.50 2252.20 -12.60 3903.10 3409.10 14.49 6756.40 4411.30 53.16
Equity 173.90 175.40 -0.86 173.90 175.40 -0.86 173.90 175.40 -0.86
PBIDTM(%) 34.63 49.83 -30.50 35.07 42.32 -17.14 37.54 32.64 14.99

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×